Pay in 4 interest-free payments of $6.13 Learn more
Ships within 48 hours · Estimated delivery Aug 13 - Aug 18
Gastrointestinal Conditions: For those with Crohn's disease, celiac disease, or post-gastric bypass surgery, injections bypass a compromised digestive system
Moderate weight loss, preserves muscle
PMC9192202 Oxyntomodulin nanofibril self-assembly NaCl neutralizes charge repulsion and drives aggregation
Diagnosis can be rather complex as the symptoms can take years for it to surface
Actorise 40 Injection Actorise 40 Injection ,
Key Safety Differentiators No IGF-1 elevation: AOD-9604 does not stimulate IGF-1, meaning it avoids risks such as organ/tissue overgrowth or acromegaly No glucose disruption: Clinical data shows it does not impair insulin sensitivity or worsen blood sugar regulation Comparable to placebo: In obesity trials, the incidence of adverse effects was similar to placebo groups, underscoring its tolerability Legal Status of AOD-9604 United States: AOD-9604 is not FDA-approved as a drug, dietary supplement, or weight loss therapy
US$ 23.72
US$ 24.66
US$ 22.55
